Article | August 8, 2023

Addressing Gaps In Cystic Fibrosis Treatment By Fixing Nonsense Mutations

Source: ElevateBio

By Alexandra Crawley, PH.D., Co-founder and Principal Investigator, Life Edit Therapeutics, Inc.

Microscope pipette GettyImages-503258063

Cell and gene therapies are enabling treatment for a number of severe or life-threatening diseases with previously unmet medical needs. Recently approved therapies for cystic fibrosis (CF) – a life-limiting disease caused by the inheritance of two recessive mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene – are able to stabilize a mutant protein, allowing it to function more normally.

However, about 7% of CF cases involve nonsense mutations in the CFTR gene, and current therapies cannot normalize the protein’s function, leaving CF patients who have these mutations with no therapeutic options. Examine how access to the world’s largest and most diverse collection of novel RGNs and deaminases is increasing the potential for addressing the needs of CF patients with nonsense mutations by helping their cells produce functional CFTR protein.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online